Autologous Bone Marrow Transplantation - Blog Science Connections

ABMT in AML With Monoclonal Antibodies 73
As shown in Table 3, major cell losses (95% on average) occurred during
the combination of the cell processing procedure and the MAb treatment,
consistent with depletion of the majority of mature myeloid cells as observed
on Wright's stained cytospin preparations of posttreatment samples.
The mean time to reach a neutrophil count of 500 cells/jul was 32 days
(Table 4). Reticulocytes appeared in the blood, on the average, by day 20 and
the hemoglobin levels were sustained at greater than 10 g/dl without transfusion
by day 48. Recovery of platelets was slow and variable.
Table 3. Number of Cells Harvested and Remaining After Cytopheresis and
MAb Treatment
Nucleated Cells
Patient Harvested 3 Postcytopheresis" Post-MAb Treatment" CFU-GM C
1 8.0 1.5 4.2 1.9
2 2.8 0.6 4.0 ND
3 2.9 0.3 3.4 ND
4 6.4 0.9 2.4 1.1
5 9.0 0.7 2.0 1.4
6 3.5 1.9 2.6 2.0
7 11.5 7.6" 3.1 0.6
8 2.5 0.4 2.7 ND
9 5.1 0.4 2.2 0.8
10 4.7 0.7 2.6 0.7
11 3.8 0.4 1.5 0.8
12 5.6 0.4 1.8 2.4
13 7.0 0.6 1.9 1.0
14 14.5 0.9 6.0 3.5
15 6.6 0.5 1.8 1.1
16 3.7 0.7 4.0 ND
Average 6.1 1.1 2.9 1.4
Abbreviations: MAb, monoclonal antibody; CFU-GM, granulocyte-macrophage
colony-forming
"Cells x 10Vkg.
unit; ND, no data.
b
Cells x 10 7 /kg. This is the actual number of cells infused. Viabilities after thawing
were >95%.
c
Cells
x 10*/kg.
"Cells from this patient were collected as a buffy coat by centrifugation. This number
was excluded from the average value.